TEST:

AVENIO ctDNA Surveillance Kit

In conclusion, tumour heterogeneity significantly influences colorectal cancer (CRC) prognosis, impacting treatment resistance and overall survival. Understanding and managing this heterogeneity are crucial for personalized medicine advancement. The autopsy and LBx analysis in this report offer insights for collective understanding of tumour evolution under therapy, guiding future research and therapeutic innovations tailored to CRC dynamics.

BNT116 + DTX shows encouraging antitumor activity, consistent induction of immune responses, a manageable safety profile, and no signs of additive toxicity. Updated safety and clinical activity data will be presented along with additional biomarker data.

Prevalence of TP53 mutations in plasma collected before osimertinib treatment initiation in advanced EGFR-mutated NSCLC was similar between patients with and without BM at baseline. Furthermore, there was no difference in the ctDNA profile between these two cohorts. Future experiments will clarify the impact of TP53 mutations in patients with or without BM.

Alternating therapy with osimertinib and afatinib for treatment-naïve patients with EGFR-mutated advanced NSCLC demonstrated encouraging efficacy. The advantages of this therapy are prevention of acquired resistance via secondary EGFR mutations, including T790M and C797S, and a broadened efficacy against various compound EGFR mutations.

This signal seeking biomarker study using cfDNA to better understand the association of mutational status and the treatment efficacy of the combined treatment was feasible and informative despite the small-scale study, supporting the advantage of further implementation.

Even in this small cohort of CRC UICC stage II/III patients, MRD detection in post-surgery plasma is the strongest predictor of shorter time to progression. Ultra-deep sequencing of cfDNA samples did not influence MRD detection on a patient-level. *for Research Use Only; not for use in diagnostic procedures.

Using NAVIFY Mutation Profiler for automated annotation, we found 17.6% of somatic variants in CRC ctDNA were of strong or potential clinical significance (Tier I or II). Using manual curation, we found only 7.9% of variants with any level of evidence in OncoKB. Furthermore, 19.6% of cases had at least 1 potentially actionable variant combination according to NAVIFY Mutation Profiler.

"Legal entity responsible for the study: Roche Sequencing Solutions, Inc. Funding: Roche Sequencing Solutions, Inc."